Clinical features and human T-cell leukemia virus type-1 (HTLV-1) proviral load in HTLV-1-positive patients with rheumatoid arthritis: Baseline data in a single center cohort study

References

• Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M. EULAR recommendation for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2016 update. Ann Rheum Dis. 2017;76(6):960–77.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Watanabe T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol. 2002;76(S2):240–5.
   PubMedGoogle Scholar
• Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388.
   PubMed Web of Science ®Google Scholar
• Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer. 1990;45(2):237–43.
   PubMed Web of Science ®Google Scholar
• Satake M, Yamaguchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol. 2012;84(2):327–35.
   PubMed Web of Science ®Google Scholar
• Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol. 2012;3:322.
   PubMed Web of Science ®Google Scholar
• Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh K-R. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116(8):1211–9.
   PubMed Web of Science ®Google Scholar
• Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4(6):586–93.
   PubMed Web of Science ®Google Scholar
• Eguchi K, Matsuoka N, Ida H, Nakashima M, Sakai M, Sakito S. Primary Sjögren’s syndrome with antibodies to HTLV-I: clinical and laboratory features. Ann Rheum Dis. 1992;51(6):769–76.
   PubMed Web of Science ®Google Scholar
• Terada K, Katamine S, Eguchi K, Moriuchi R, Kita M, Shimada H, et al. Prevalence of serum and salivary antibodies to HTLV-1 in Sjögren’s syndrome. Lancet. 1994;344(8930):1116–9.
   PubMed Web of Science ®Google Scholar
• Eguchi K, Origuchi T, Takashima H, Iwata K, Katamine S, Nagataki S. High seroprevalence of anti-HTLV-I antibody in rheumatoid arthritis. Arthritis Rheum. 1996;39(3):463–6.
   PubMed Web of Science ®Google Scholar
• Hida A, Imaizumi M, Sera N, Akahoshi M, Soda M, Maeda R, et al. Association of human T lymphotropic virus type I with Sjögren syndrome. Ann Rheum Dis. 2010;69(11):2056–67.
   PubMed Web of Science ®Google Scholar
• Kawakami A, Eguchi K. Role of HTLV-I infection in the pathogenesis of Sjögren’s syndrome and rheumatoid arthritis. Mod Rheumatol. 2001;11(2):87–90.
   PubMedGoogle Scholar
• Nakamura H, Ueki Y, Saito S, Horai Y, Suzuki T, Naoe T, et al. Development of adult T-cell leukemia in a patient with rheumatoid arthritis treated with tocilizumab. Intern Med. 2013;52(17):1983–6.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Eguchi K, Hida A, Terada K, Aramaki T, Nonaka F, et al. Development of adult T-cell leukemia/lymphoma during the treatment of rheumatoid arthritis. Mod Rheumatol Case Reports. 2019;3:1–5.
   Google Scholar
• Shiraishi T, Ishimoto H, Akata K, Kawanami T, Yatera K, Mukae H. An autopsy case report of adult T-cell leukemia accompanied by rheumatoid arthritis mimicking diffuse panbronchiolitis. J Uoeh. 2017;39(1):55–61. [In Japanese]
   PubMedGoogle Scholar
• Takajo I, Umekita K, Ikei Y, Oshima K, Okayama A. Adult T-cell leukemia/lymphoma as a methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis. A case report. Intern Med. 2018;57(14):2071–5.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum.1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.
   PubMed Web of Science ®Google Scholar
• Steinbrocker O, Traeger CH, Batterman CR. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140(8):659.
   PubMed Web of Science ®Google Scholar
• Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res. 2012;64(5):640–7.
   PubMed Web of Science ®Google Scholar
• Kamihira S, Dateki N, Sugahara K, Hayashi T, Harasawa H, Minami S, et al. Significance of HTLV-1 proviral load quantification by real-time PCR as a surrogate marker for HTLV-1-infected cell count. Clin Lab Haematol. 2003;25(2):111–7.
   PubMedGoogle Scholar
• Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, STROBE Initiative, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297.
   PubMed Web of Science ®Google Scholar
• Umekita K, Hashiba Y, Kariya Y, Kubo K, Miyauchi S, Aizawa A, et al. The time-sequential changes of risk factors for adult T-cell leukemia development in human T-cell leukemia virus-positive patients with rheumatoid arthritis: a retrospective cohort study. Mod Rheumatol. 2018;1–7. doi:10.1080/14397595.2018.1519890.
   PubMed Web of Science ®Google Scholar
• Yakova M, Lezin A, Dantin F, Lagathu G, Olindo S, Jean-Baptiste G, et al. Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology. 2005;2:4.
   PubMed Web of Science ®Google Scholar
• Hashiba Y, Hidaka T, Umekita K, Nishi E, Kai Y, Kubo K, et al. Remission of chronic type ATL in a patient with rheumatoid arthritis after withdrawing methotrexate and anti-TNFα biologic combination therapy; a case report. Modern Rheum Case Reports. 2018;2(1):9–13.
   Google Scholar
• Shimamoto Y, Nomura S, Ishii K, Shimizu M, Ozaki Y, Ito T, et al. Adult T-cell leukemia after immunosuppressive therapy for systemic lupus erythematosus. Int J Hematol. 2009;89(1):128–9.
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Bauer F, Ichim TE, Vyas D, Ek K, Alexandrescu DT. Rapidly fatal acute ATLL emerging after methotrexate therapy for disseminated psoriasis. Clin Lymphoma Myeloma Leuk. 2012;12(1):76–8.
   PubMed Web of Science ®Google Scholar
• Bittencourt AL, Oliveira PD, Bittencourt VG, Carvalho EM, Farre L. Adult T-cell leukemia/lymphoma triggered by adalimumab. J Clin Virol. 2013;58(2):494–6.
   PubMed Web of Science ®Google Scholar
• Kawano N, Shimoda K, Ishikawa F, Taketomi A, Yoshizumi T, Shimoda S, et al. Adult T-cell leukemia development from a human T-cell leukemia virus type I carrier after a living-donor liver transplantation. Transplantation. 2006;82(6):840–3.
   PubMed Web of Science ®Google Scholar
• Nakamura N, Tamaru S, Ohshima K, Tanaka M, Arakaki Y, Miyauchi T. Prognosis of HTLV-1 positive renal transplant recipients. Transplant Proc. 2005;37(4):1779–82.
   PubMed Web of Science ®Google Scholar
• Kawano N, Yoshida S, Kawano S, Kuriyama T, Tahara Y, Toyofuku A, et al. The clinical impact of human T-lymphotrophic virus type 1 (HTLV-1) infection on the development of adult T-cell leukemia-lymphoma (ATL) or HTLV-1-associated myelopathy (HAM) / atypical HAM after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and renal transplantation. J Clin Exp Hematop. 2018;58(3):107–21.
   PubMed Web of Science ®Google Scholar
• Dias ARN, Falcao LFM, Falcao ASC, Normando VMF, Quaresma J. Human T lymphotropic virus and pulmonary diseases. Front Microbiol. 2018;9:1879.
   PubMed Web of Science ®Google Scholar
• Imaizumi Y, Iwanaga M, Tsukasaki K, Hata T, Tomonaga M, Ikeda S. Natural course of HTLV-1 carriers with monoclonal proliferation of T lymphocytes (“pre-ATL”) in a 20-year follow-up study. Blood. 2005;105(2):903–4.
   PubMed Web of Science ®Google Scholar
• Quaresma J, Yoshikawa G, Koyama R, Dias G, Fujihara S, Fuzii H. HTLV-1, immune response and autoimmunity. Viruses. 2015;8(1):5.
   Web of Science ®Google Scholar
• Arisawa K, Soda M, Akahoshi M, Fujiwara S, Uemura H, Hiyoshi M, et al. Human T-cell lymphotropic virus type-1 infection and risk of cancer: 15.4 year longitudinal study among atomic bomb survivors in Nagasaki, Japan. Cancer Sci. 2006;97(6):535–9.
   PubMed Web of Science ®Google Scholar
• Winthrpo KL. The emerging safety profile of JAK inhibitors in rheumatic diseases. Nat Rev Rheumatol. 2017;13:234–43.
   PubMed Web of Science ®Google Scholar
• Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene. 2011;30(12):1379–89.
   PubMed Web of Science ®Google Scholar
• Enose-Akahata Y, Vellucci A, Jacobson S. Role of HTLV-1 Tax and HBZ in the pathogenesis of HAM/TSP. Front Microbiol. 2017;8:2563.
   PubMed Web of Science ®Google Scholar
• Kawatsuki A, Yasunaga JI, Mitobe Y, Green PL, Matsuoka M. HTLV-1 bZIP factor protein targets the Rb/E2F-1 pathway to promote proliferation and apoptosis of primary CD4+ T cells. Oncogene. 2016;35(34):4509–17.
   PubMed Web of Science ®Google Scholar